Abstract:A 61-yr-old previously fit lorry driver was referred by his general practitioner in October 1999 to an orthopaedic clinic with a 6-month history of painful hands, shoulders and feet. His general practitioner had treated him with ibuprofen without much improvement. He admitted to a recent history of loss of appetite with loss of two stones (12.7 kg) in weight. His joint pains had been increasing in severity with visible swelling of his fingers and knees. He had no relevant family history. He was an ex-smoker and drank little alcohol. Physical examination revealed a healthy-looking man with signs of synovitis in the symptomatic joints. The orthopaedic surgeon referred him to the rheumatologist (K.C.). The preliminary blood tests showed haemoglobin of 10.4 g/dl with normal haematocrit, leucocyte and platelet counts and normal serum vitamin B12 and red-cell folate levels. His serum ferritin was 468 g/l (normal range 18–400 g/l). He also had transient random hyperglycaemia, which was followed by a normal glucose tolerance test. His rheumatoid factor was elevated at 1:2560. His chest X-ray was normal except for some thickening of the bronchiolar wall. He was seen in the rheumatology clinic 2 months later, in December 1999, with classical symptoms and signs of a symmetrical inflammatory polyarthritis suggestive of rheumatoid disease. His knees were drained and injected with methyl prednisolone and local anaesthetic. He was also given intramuscular methyl prednisolone (120mg) to induce remission of active disease. Investigations revealed haemoglobin 10.3 g/dl, white cell count 6.4 10/l, platelet count 449 l0/l and ESR of 100mm in the first hour. The biochemical screens were all normal, including liver, renal and bone panels. The rheumatoid factor was 2460 IU (normal range 30 IU) and CRP was elevated at 85.1mg/dl (normal range <10mg/dl). The X-rays of his hands and feet showed no obvious erosions. The option of commencing methotrexate as a second-line drug was discussed but he preferred to wait until he returned from a planned Christmas holiday in Spain. Soon after his return from holiday he developed sudden severe cramp-like pains associated with numbness in his legs. He was virtually unable to walk. An MRI scan of his whole spine was done on the advice of the neurosurgeons, and, as the scans were normal, he was referred to the neurologists, who performed a lumbar puncture to exclude acute infective polyneuritis. The neurologists also noted a skin rash on his legs associated with left foot drop (Fig. 1). An autoimmune disease was suspected and the rheumatologist (K.C.) was consulted. On examination he had a vasculitic rash with peripheral neuropathy. There was no lymphadenopathy or organomegaly. Given the recent diagnosis of seropositive rheumatoid arthritis (RA), systemic rheumatoid vasculitis (SRV) seemed to be the most plausible diagnosis. Investigations at this time revealed haemoglobin 9.0 g/dl, white cell count 12.1 10/l and neutrophils 9.6 10/l with normal platelet and lymphocyte count. The ESR was 110mm in the first hour and CRP was 121mg/dl (normal range <5mg/dl). The biochemical, serological and microbiological screens including hepatitis A, B and C were all normal/negative. His anti nuclear antibodies, anti DNA antibodies, extractable nuclear antigens, anti cardiolipin antibodies, anti neutrophil cytoplasmic antibodies and cryoglobulins were all negative. Echocardiogram was normal. A cerebrospinal fluid study showed a mild increase in cerebrospinal fluid protein but no oligoclonal band or albumino-cytological dissociation. Electromyography showed severe sensorimotor polyneuropathy of the axonal type with some denervation changes in the peroneal muscles. A skin biopsy confirmed active necrotizing vasculitis, consistent with SRV (Fig. 2). He was commenced on pulse intravenous methyl prednisolone (500mg) and cyclophosphamide (500mg) with some symptomatic improvement, and was discharged home on a 2-weekly regime.

Fabrication and Evaluation of a Bioactive Sr–Ca–P Contained Micro-Arc Oxidation Coating on Magnesium Strontium Alloy for Bone Repair Application

Micro-arc oxidation-assisted sol-gel preparation of calcium metaphosphate coatings on magnesium alloys for bone repair

In vitro and in vivo degradation, biocompatibility and bone repair performance of strontium doped montmorillonite coating on Mg-Ca alloy

Dual-functional coatings on magnesium alloys: Enhancing corrosion behavior under stress and osteogenic effect in osteoporotic rats

Preparing Ca-P Coating on Biodegradable Magnesium Alloy by Hydrothermal Method: in Vitro Degradation Behavior

Effect of Strontium-Substituted Calcium Phosphate Coatings Prepared by One-Step Electrodeposition at Different Temperatures on Corrosion Resistance and Biocompatibility of AZ31 Magnesium Alloys

In Vitro Corrosion and Cytocompatibility of A Microarc Oxidation Coating and Poly(L-Lactic Acid) Composite Coating on Mg-1li-1ca Alloy for Orthopedic Implants

A novel Ca-Mg-P/PDA composite coating of Mg alloys to improve corrosion resistance for orthopedic implant materials

Surface Engineering of Biodegradable Magnesium Alloys for Enhanced Orthopedic Implants.

Defects of cholecystokinin (CCK)-A receptor gene expression and CCK-A receptor-mediated biological functions in Otsuka Long-Evans Tokushima Fatty (OLETF) rats

Metal-organic complex coating for enhanced corrosion control and biocompatibility on biodegradable magnesium alloy for orthopaedic implants

A Systematic Review and Network Meta-Analysis of Biomedical Mg Alloy and Surface Coatings in Orthopedic Application

The effect of different coatings on bone response and degradation behavior of porous magnesium-strontium devices in segmental defect regeneration

Bone regeneration of hollow tubular magnesium‑strontium scaffolds in critical-size segmental defects: Effect of surface coatings

Corrosion Resistance and Biocompatibility of Calcium Phosphate Coatings with a Micro-Nanofibrous Porous Structure on Biodegradable Magnesium Alloys

A conversation with AAOS president Frederick M. Azar, MD.

In Vivo Degradation Behavior of Magnesium Alloy for Bone Implants with Improving Biological Activity, Mechanical Properties, and Corrosion Resistance

Bioactivity enhancement by Sr doped Zn-Ca-P coatings on biomedical magnesium alloy

Rheumatoid arthritis, pyrexia of unknown origin (PUO) and pancytopenia.

Characterization and Degradation Study of Calcium Phosphate Coating on Magnesium Alloy Bone Implant in Vitro

Self-Healing Micro Arc Oxidation and Dicalcium Phosphate Dihydrate Double-Passivated Coating on Magnesium Membrane for Enhanced Bone Integration Repair